In fiscal 2025, which ended May 25, 2025, Lifecore Biomedical, Inc. reported revenue of $128.9 million, up 0.5% from the year before. It recorded a net loss of $38.7 million. The operating loss came to $17.2 million, an operating margin of -13.4%. Diluted earnings per share were -$1.27. Over the twelve months ended Sep 30, 2026, revenue was $119.1 million and the net loss was $62.4 million. Across the 10 fiscal years shown, revenue shrank from $541.1 million in fiscal 2016 to $128.9 million in fiscal 2025, about 14.7% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
May 25, 2025
|
FY 2024
May 26, 2024
|
FY 2023
May 28, 2023
|
FY 2022
May 29, 2022
|
FY 2021
May 30, 2021
|
FY 2020
May 31, 2020
|
FY 2019
May 26, 2019
|
FY 2018
May 27, 2018
|
FY 2017
May 28, 2017
|
FY 2016
May 29, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
119
-8.6%
|
129
+0.5%
|
128
+24.2%
|
103
-7.2%
|
111
+10.3%
|
101
-37.0%
|
160
-71.3%
|
558
+6.4%
|
524
-1.5%
|
532
-1.6%
|
541
+0.3%
|
| Cost of revenue |
82
-5.7%
|
89
+2.5%
|
86
+14.8%
|
75
+4.3%
|
72
+16.6%
|
62
-48.7%
|
121
-74.7%
|
477
+6.9%
|
446
-0.7%
|
449
-4.5%
|
470
-0.8%
|
| Gross profit |
37
-14.3%
|
40
-3.7%
|
42
+49.5%
|
28
-28.4%
|
39
+0.3%
|
39
-1.1%
|
39
-51.4%
|
81
+3.4%
|
78
-1.1%
|
79
+18.6%
|
67
+2.1%
|
| Research and development |
6
-24.5%
|
8
-3.7%
|
9
-1.8%
|
9
+11.4%
|
8
+17.3%
|
7
-11.8%
|
8
-33.9%
|
11
-10.4%
|
13
+35.1%
|
9
+31.1%
|
7
+3.4%
|
| Selling, general and administrative |
31
-34.1%
|
44
+8.9%
|
40
+3.8%
|
39
+12.4%
|
35
+25.0%
|
28
-31.8%
|
41
-34.5%
|
62
+19.5%
|
52
-1.0%
|
52
+13.7%
|
46
+15.6%
|
| Restructuring and impairment |
-3
-266.8%
|
-2
-205.5%
|
2
-60.4%
|
4
-49.9%
|
8
-37.4%
|
13
+229.4%
|
4
|
—
|
—
|
—
|
—
|
| Operating income |
2
+111.4%
|
-17
-95.0%
|
-9
+59.4%
|
-22
-84.9%
|
-12
-33.6%
|
-9
+65.9%
|
-26
-572.6%
|
5
-59.7%
|
14
-7.4%
|
15
+171.1%
|
-21
-211.7%
|
| Pretax income |
-62
-39.2%
|
-39
-506.5%
|
10
+114.9%
|
-64
-209.0%
|
-21
+30.6%
|
-30
+2.8%
|
-31
-941.9%
|
4
-77.8%
|
16
+15.7%
|
14
|
—
|
| Income tax |
0
+419.1%
|
0
-76.5%
|
0
-40.6%
|
0
+105.9%
|
-5
+17.9%
|
-6
+27.6%
|
-9
-678.0%
|
2
+116.2%
|
-9
-331.8%
|
4
+152.4%
|
-8
-199.5%
|
| Net income |
-62
-39.7%
|
-39
-422.3%
|
12
+112.1%
|
-100
+14.7%
|
-117
-261.4%
|
-32
+15.4%
|
-38
-9392.2%
|
0
-98.3%
|
25
+134.5%
|
11
+191.0%
|
-12
-185.9%
|
| Net income to common |
-66
|
-44
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Basic EPS |
-1.76
-31.2%
|
-1.27
-425.6%
|
0.39
+111.7%
|
-3.32
+16.4%
|
-3.97
-260.9%
|
-1.10
+16.0%
|
-1.31
-13200.0%
|
0.01
-98.9%
|
0.90
+130.8%
|
0.39
+190.7%
|
-0.43
-186.0%
|
| Diluted EPS |
-1.76
-37.8%
|
-1.27
-484.8%
|
0.33
+109.9%
|
-3.32
+16.4%
|
-3.97
-260.9%
|
-1.10
+16.0%
|
-1.31
-13200.0%
|
0.01
-98.9%
|
0.89
+134.2%
|
0.38
+188.4%
|
-0.43
-186.0%
|
| Weighted average shares, basic |
37
+12.9%
|
35
+14.3%
|
30
+1.7%
|
30
+1.7%
|
29
+0.6%
|
29
+0.5%
|
29
+2.8%
|
28
+3.0%
|
28
+0.9%
|
27
+0.9%
|
27
+0.6%
|
| Weighted average shares, diluted |
37
+7.5%
|
35
-5.0%
|
37
+22.4%
|
30
+1.7%
|
29
+0.6%
|
29
+0.5%
|
29
+1.9%
|
29
+2.5%
|
28
+1.0%
|
28
+2.2%
|
27
-1.1%
|
| Other measures | |||||||||||
| Depreciation and amortization |
—
|
8
+0.9%
|
8
-39.6%
|
13
-27.0%
|
18
-9.1%
|
20
+5.5%
|
19
+23.7%
|
15
+22.7%
|
12
+16.2%
|
11
+13.6%
|
9
+32.5%
|
| EBITDA |
—
|
-9
-935.7%
|
-1
+89.7%
|
-9
-237.5%
|
6
-43.2%
|
11
+256.9%
|
-7
-134.0%
|
21
-20.4%
|
26
+2.6%
|
25
+325.6%
|
-11
-144.0%
|
| Interest coverage |
—
|
—
|
—
|
-1.23x
|
-0.76x
|
—
|
—
|
—
|
—
|
—
|
-10.38x
|
| Margins | |||||||||||
| Gross margin |
31.35%
|
31.27%
|
32.63%
|
27.10%
|
35.11%
|
38.60%
|
24.61%
|
14.53%
|
14.94%
|
14.88%
|
12.34%
|
| Operating margin |
1.95%
|
-13.38%
|
-6.90%
|
-21.11%
|
-10.60%
|
-8.75%
|
-16.17%
|
0.98%
|
2.59%
|
2.76%
|
-3.81%
|
| Pretax margin |
-52.23%
|
-30.01%
|
7.42%
|
-61.90%
|
-18.59%
|
-29.53%
|
-19.15%
|
0.65%
|
3.13%
|
2.66%
|
—
|
| Profit margin |
-52.35%
|
-30.04%
|
9.37%
|
-96.41%
|
-104.89%
|
-32.01%
|
-23.86%
|
0.07%
|
4.74%
|
1.99%
|
-2.15%
|
| EBITDA margin |
—
|
-7.15%
|
-0.69%
|
-8.35%
|
5.63%
|
10.95%
|
-4.40%
|
3.71%
|
4.96%
|
4.76%
|
-2.08%
|
| Effective tax rate |
—
|
—
|
1.92%
|
—
|
—
|
—
|
—
|
41.70%
|
-57.10%
|
28.50%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LFCR (Nasdaq)
- Fiscal year ends
- May 25
- Incorporated in
- DE
- Headquarters
- Chaska, MN
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1005286
- Former names
- LANDEC CORP \CA\ (until Nov 7, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.